Response

Affiliations

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD (JCG, MS, HAK, NW); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (PEC); Regional Laboratory, Kaiser Permanente Northern California, Berkeley, CA (BF, NEP, TL); Information Management Services Inc., Calverton, MD (LCC); Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, CA (WKK). gagej@mail.nih.gov.
² Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD (JCG, MS, HAK, NW); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (PEC); Regional Laboratory, Kaiser Permanente Northern California, Berkeley, CA (BF, NEP, TL); Information Management Services Inc., Calverton, MD (LCC); Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, CA (WKK).

Comment

Julia C Gage et al. J Natl Cancer Inst. 2014.

. 2014 Dec 26;107(1):390.

doi: 10.1093/jnci/dju390. Print 2015 Jan.

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD (JCG, MS, HAK, NW); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (PEC); Regional Laboratory, Kaiser Permanente Northern California, Berkeley, CA (BF, NEP, TL); Information Management Services Inc., Calverton, MD (LCC); Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, CA (WKK). gagej@mail.nih.gov.
² Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD (JCG, MS, HAK, NW); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (PEC); Regional Laboratory, Kaiser Permanente Northern California, Berkeley, CA (BF, NEP, TL); Information Management Services Inc., Calverton, MD (LCC); Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, CA (WKK).

No abstract available

Comment on

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK. Gage JC, et al. J Natl Cancer Inst. 2014 Jul 18;106(8):dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 25038467 Free PMC article.
RE: reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Rabin DS. Rabin DS. J Natl Cancer Inst. 2014 Dec 26;107(1):369. doi: 10.1093/jnci/dju369. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25542964 No abstract available.
RE: Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Greenspan D. Greenspan D. J Natl Cancer Inst. 2014 Dec 26;107(1):374. doi: 10.1093/jnci/dju374. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25542965 No abstract available.

1. Wentzensen N, Wacholder S. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov. 2013;3(2): 148–157. - PMC - PubMed
1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172. - PMC - PubMed
1. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880–891, W312. - PubMed
1. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222–1238. - PubMed
1. Castle PE, Stoler MH, Wright TC, Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–890. - PubMed